MeSH term
Frequency | Condition_Probility | Apolipoproteins C/*genetics | 22 | 24.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Comparative Study | 7 | 0.0 |
Genotype | 14 | 0.0 |
Humans | 56 | 0.0 |
Male | 33 | 0.0 |
Middle Aged | 22 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 38 | 0.0 |
Triglycerides/*blood | 5 | 1.0 |
Adult | 23 | 0.0 |
Aged | 6 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Base Sequence | 4 | 0.0 |
Female | 28 | 0.0 |
Genetic Markers | 4 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
*Polymorphism, Genetic | 12 | 0.0 |
Reference Values | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Amino Acid Substitution/*genetics | 2 | 3.0 |
Apolipoproteins B/blood/genetics | 2 | 33.0 |
Cardiovascular Diseases/genetics | 2 | 7.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 18 | 0.0 |
Apolipoproteins E/*genetics | 5 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Lipids/*blood | 8 | 1.0 |
Lipoproteins, HDL Cholesterol/blood | 6 | 0.0 |
Triglycerides/blood | 4 | 0.0 |
Alleles | 14 | 0.0 |
Apolipoprotein A-I/blood | 2 | 1.0 |
Apolipoproteins C/genetics | 5 | 14.0 |
Apolipoproteins E/genetics | 5 | 1.0 |
Cohort Studies | 7 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 4 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Risk Factors | 6 | 0.0 |
Adolescent | 7 | 0.0 |
Age Factors | 2 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Child | 5 | 0.0 |
Cholesterol/blood | 7 | 0.0 |
Coronary Disease/genetics | 2 | 5.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Gene Frequency | 10 | 0.0 |
*Glycoproteins | 5 | 0.0 |
Lipase/*genetics | 3 | 8.0 |
Lipoprotein Lipase/*genetics | 4 | 2.0 |
Liver/enzymology | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Apolipoproteins/*genetics | 5 | 7.0 |
Arteriosclerosis/etiology/*genetics | 2 | 50.0 |
Diet | 2 | 0.0 |
Postprandial Period | 2 | 2.0 |
Arteriosclerosis/*genetics | 2 | 7.0 |
Glucose/*metabolism | 2 | 1.0 |
Lipids/blood | 5 | 0.0 |
Lipoproteins/blood | 3 | 0.0 |
Carrier Proteins/genetics | 4 | 1.0 |
Polymorphism, Genetic | 7 | 0.0 |
Cardiovascular Diseases/blood/*genetics | 3 | 25.0 |
France | 2 | 0.0 |
Apolipoproteins B/genetics | 4 | 10.0 |
Czech Republic | 2 | 4.0 |
Sex Factors | 3 | 0.0 |
Animals | 7 | 0.0 |
Coronary Disease/*genetics | 2 | 3.0 |
*Variation (Genetics) | 3 | 0.0 |
*Diet | 2 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Neoplasm Proteins | 3 | 0.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
Apolipoproteins B/blood | 3 | 1.0 |
Apolipoproteins C/blood/*genetics | 2 | 25.0 |
Multigene Family | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Mice | 5 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Arteriosclerosis/etiology | 2 | 2.0 |
Lipoproteins/*blood | 7 | 1.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
Haplotypes | 2 | 0.0 |
*Haplotypes | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Risk | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Linkage Disequilibrium/genetics | 3 | 1.0 |
India | 2 | 0.0 |
Aryldialkylphosphatase | 3 | 1.0 |
Body Mass Index | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Esterases/genetics | 2 | 11.0 |
Indians, North American/*genetics | 2 | 2.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Lipoprotein Lipase/genetics | 2 | 6.0 |
Apolipoprotein A-I/*genetics | 2 | 6.0 |
Apolipoproteins A/*genetics | 5 | 10.0 |
Linkage Disequilibrium | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Particle Size | 2 | 0.0 |
DNA/*genetics | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Apolipoprotein A-I | 3 | 2.0 |
Recombination, Genetic | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
